$216 Million is the total value of Parkman Healthcare Partners LLC's 66 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 72.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GWPH | Buy | GW PHARMACEUTICALS PLCads | $10,752,000 | +8.2% | 122,778 | +29.2% | 4.98% | +73.8% |
| UNH | Buy | UNITEDHEALTH GROUP INC | $8,728,000 | +18.7% | 35,000 | +40.0% | 4.04% | +90.6% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $6,694,000 | -13.2% | 590,267 | +0.4% | 3.10% | +39.4% |
| AXNX | Buy | AXONICS MODULATION TECHNOLOG | $6,147,000 | +33.5% | 241,909 | +45.5% | 2.85% | +114.2% |
| DRNA | Buy | DICERNA PHARMACEUTICALS INC | $5,526,000 | +4.5% | 300,805 | +25.3% | 2.56% | +67.8% |
| ICAD | Buy | ICAD INC | $5,326,000 | +14.1% | 725,590 | +20.8% | 2.47% | +83.2% |
| MNTA | New | MOMENTA PHARMACEUTICALS INC | $4,772,000 | – | 175,453 | +100.0% | 2.21% | – |
| AVRO | Buy | AVROBIO INC | $4,599,000 | +153.8% | 295,593 | +228.4% | 2.13% | +307.5% |
| MTEM | Buy | MOLECULAR TEMPLATES INC | $4,557,000 | -4.6% | 342,875 | +0.3% | 2.11% | +53.0% |
| KRMD | Buy | REPRO MED SYS INC | $4,290,000 | +24.3% | 571,985 | +8.2% | 1.99% | +99.4% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $3,958,000 | -1.8% | 36,363 | +3.9% | 1.83% | +57.6% |
| SDGR | New | SCHRODINGER INC | $3,453,000 | – | 80,071 | +100.0% | 1.60% | – |
| XLRN | New | ACCELERON PHARMA INC | $3,370,000 | – | 37,500 | +100.0% | 1.56% | – |
| ITMR | Buy | ITAMAR MED LTDsponsored ads | $3,129,000 | +418.0% | 265,650 | +466.4% | 1.45% | +733.3% |
| NUAN | New | NUANCE COMMUNICATIONS INC | $2,518,000 | – | 150,056 | +100.0% | 1.17% | – |
| IRMD | Buy | IRADIMED CORP | $2,431,000 | +11.2% | 113,855 | +21.8% | 1.13% | +78.6% |
| MRNA | New | MODERNA INC | $2,246,000 | – | 75,000 | +100.0% | 1.04% | – |
| BBIO | New | BRIDGEBIO PHARMA INC | $2,181,000 | – | 75,215 | +100.0% | 1.01% | – |
| SAGE | New | SAGE THERAPEUTICS INC | $2,154,000 | – | 75,000 | +100.0% | 1.00% | – |
| SPNE | Buy | SEASPINE HLDGS CORP | $2,008,000 | +48.7% | 245,785 | +118.6% | 0.93% | +138.7% |
| MDGL | New | MADRIGAL PHARMACEUTICALS INC | $2,003,000 | – | 30,000 | +100.0% | 0.93% | – |
| KALA | New | KALA PHARMACEUTICALS INC | $1,978,000 | – | 225,000 | +100.0% | 0.92% | – |
| STXS | Buy | STEREOTAXIS INC | $1,974,000 | -29.8% | 653,693 | +22.9% | 0.92% | +12.7% |
| XENT | Buy | INTERSECT ENT INC | $1,966,000 | -37.1% | 165,923 | +32.2% | 0.91% | +1.0% |
| AUPH | Buy | AURINIA PHARMACEUTICALS INC | $1,745,000 | -13.9% | 120,288 | +20.3% | 0.81% | +38.3% |
| New | TRILLIUM THERAPEUTICS INC | $1,717,000 | – | 425,000 | +100.0% | 0.80% | – | |
| MGTX | Buy | MEIRAGTX HOLDINGS PLC | $1,680,000 | +1.9% | 125,000 | +51.9% | 0.78% | +63.7% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $1,599,000 | +276.2% | 1,537,357 | +583.3% | 0.74% | +502.4% |
| NEPH | Buy | NEPHROS INC | $1,584,000 | -20.3% | 251,366 | +25.9% | 0.73% | +27.9% |
| INFU | Buy | INFUSYSTEM HLDGS INC | $1,447,000 | +35.7% | 170,483 | +36.4% | 0.67% | +117.9% |
| MNLO | New | MENLO THERAPEUTICS INC | $1,089,000 | – | 406,383 | +100.0% | 0.50% | – |
| APRE | New | APREA THERAPEUTICS INC | $1,044,000 | – | 30,036 | +100.0% | 0.48% | – |
| CBIO | New | CATALYST BIOSCIENCES INC | $941,000 | – | 215,237 | +100.0% | 0.44% | – |
| MBIO | Buy | MUSTANG BIO INC | $813,000 | -34.1% | 303,376 | +0.4% | 0.38% | +5.9% |
| New | CATABASIS PHARMACEUTICALS IN | $645,000 | – | 155,473 | +100.0% | 0.30% | – | |
| IMVT | New | IMMUNOVANT INC | $625,000 | – | 40,125 | +100.0% | 0.29% | – |
| APYX | Buy | APYX MED CORP | $127,000 | -57.5% | 35,497 | +0.3% | 0.06% | -31.4% |
| CLPT | New | CLEARPOINT NEURO INC | $90,000 | – | 25,078 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DEXCOM INC | 16 | Q3 2023 | 6.3% |
| ACLARIS THERAPEUTICS INC | 16 | Q3 2023 | 10.0% |
| XENON PHARMACEUTICALS INC | 16 | Q3 2023 | 3.3% |
| NATERA INC | 16 | Q3 2023 | 3.4% |
| AVID BIOSERVICES INC | 15 | Q3 2023 | 2.9% |
| SCHRODINGER INC | 15 | Q3 2023 | 4.2% |
| REPRO MED SYS INC | 15 | Q2 2023 | 2.0% |
| MANNKIND CORP | 15 | Q3 2023 | 1.6% |
| IQVIA HLDGS INC | 14 | Q1 2023 | 4.6% |
| INSULET CORP | 14 | Q3 2023 | 2.9% |
View Parkman Healthcare Partners LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PLUS THERAPEUTICS, INC. | February 13, 2023 | 583,467 | 1.7% |
View Parkman Healthcare Partners LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-13 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Parkman Healthcare Partners LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.